<SEC-DOCUMENT>0001193125-24-242319.txt : 20241024
<SEC-HEADER>0001193125-24-242319.hdr.sgml : 20241024
<ACCEPTANCE-DATETIME>20241024082804
ACCESSION NUMBER:		0001193125-24-242319
CONFORMED SUBMISSION TYPE:	424B3
PUBLIC DOCUMENT COUNT:		2
FILED AS OF DATE:		20241024
DATE AS OF CHANGE:		20241024

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			KAZIA THERAPEUTICS LTD
		CENTRAL INDEX KEY:			0001075880
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			C3
		FISCAL YEAR END:			0630

	FILING VALUES:
		FORM TYPE:		424B3
		SEC ACT:		1933 Act
		SEC FILE NUMBER:	333-276774
		FILM NUMBER:		241390804

	BUSINESS ADDRESS:	
		STREET 1:		THREE INTERNATIONAL TOWERS LEVEL 24,
		STREET 2:		300 BARANGAROO AVENUE
		CITY:			SYDNEY NSW
		STATE:			C3
		ZIP:			2000
		BUSINESS PHONE:		01161298780088

	MAIL ADDRESS:	
		STREET 1:		THREE INTERNATIONAL TOWERS LEVEL 24,
		STREET 2:		300 BARANGAROO AVENUE
		CITY:			SYDNEY NSW
		STATE:			C3
		ZIP:			2000

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	NOVOGEN LTD
		DATE OF NAME CHANGE:	19981228
</SEC-HEADER>
<DOCUMENT>
<TYPE>424B3
<SEQUENCE>1
<FILENAME>d887400d424b3.htm
<DESCRIPTION>424B3
<TEXT>
<HTML><HEAD>
<TITLE>424B3</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE" STYLE="line-height:Normal">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Filed Pursuant to Rule 424(b)(3) <BR> Registration No. 333-276774 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>PROSPECTUS SUPPLEMENT </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>(to Prospectus dated
February&nbsp;5, 2024) </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>4,755,556 American Depositary Shares representing 47,555,560 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>Ordinary Shares </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g887400g1023022454667.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:24pt; font-family:Times New Roman" ALIGN="center"><B>Kazia Therapeutics Limited </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This prospectus supplement is being filed to update and supplement the information contained in the prospectus dated February&nbsp;5, 2024 (the
&#147;Prospectus&#148;), which forms a part of our Registration Statement on Form <FONT STYLE="white-space:nowrap">F-1</FONT> (Registration <FONT STYLE="white-space:nowrap">No.&nbsp;333-276774),</FONT> with the information contained in Amendment
No.&nbsp;1 to our current report on Form <FONT STYLE="white-space:nowrap">6-K,</FONT> furnished to the Securities and Exchange Commission on October&nbsp;24, 2024 (the &#147;October 24, 2024 Form <FONT STYLE="white-space:nowrap">6-K/A&#148;).</FONT>
Accordingly, we have attached the October&nbsp;24, 2024 Form <FONT STYLE="white-space:nowrap">6-K/A</FONT> to this prospectus supplement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This prospectus
supplement updates and supplements the information in the Prospectus and is not complete without, and may not be delivered or utilized except in combination with, the Prospectus, including any amendments or supplements thereto. This prospectus
supplement should be read in conjunction with the Prospectus and if there is any inconsistency between the information in the Prospectus and this prospectus supplement, you should rely on the information in this prospectus supplement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The ADSs are listed on The Nasdaq Capital Market (&#147;Nasdaq&#148;) under the symbol &#147;KZIA.&#148; On October&nbsp;23, 2024, the last reported sale
price of the ADSs on Nasdaq was $0.5793&nbsp;per ADS. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman"><B>Investing in our securities
involves a high degree of risk. See &#147;Risk Factors&#148; beginning on page 9 of the Prospectus and the &#147;Risk Factors&#148; in &#147;Item 3. Key Information&#151;D. Risk Factors&#148; of our most recent Annual Report on Form <FONT
STYLE="white-space:nowrap">20-F,</FONT> which is incorporated by reference in the Prospectus, as well as in any other recently filed reports and, if any, in any applicable prospectus supplement. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Neither the Securities and Exchange Commission nor any state securities commission has approved or disapproved of these securities or passed upon the
adequacy or accuracy of the Prospectus or this prospectus supplement. Any representation to the contrary is a criminal offense. </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>The date of
this prospectus supplement is October&nbsp;24, 2024 </B></P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>UNITED STATES </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>SECURITIES AND EXCHANGE COMMISSION </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Washington, D.C. 20549 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>Form <FONT
STYLE="white-space:nowrap">6-K/A</FONT></B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>REPORT OF
FOREIGN PRIVATE ISSUER </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>PURSUANT TO RULE <FONT STYLE="white-space:nowrap">13a-16</FONT> OR
<FONT STYLE="white-space:nowrap">15d-16</FONT></B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>UNDER THE SECURITIES EXCHANGE ACT OF 1934 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>For the month of October, 2024 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Commission File Number <FONT STYLE="white-space:nowrap">000-29962</FONT></B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:24pt; font-family:Times New Roman" ALIGN="center"><B>Kazia Therapeutics Limited </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(Translation of registrant&#146;s name into English) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Three
International Towers Level&nbsp;24 300 Barangaroo Avenue Sydney NSW 2000 </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Address of principal executive office) </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark whether the registrant files or will file annual reports under cover of Form <FONT STYLE="white-space:nowrap">20-F</FONT> or Form <FONT
STYLE="white-space:nowrap">40-F.</FONT></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Form <FONT STYLE="white-space:nowrap">20-F&#8194;&#9746;&#8195;&#8195;&#8195;Form</FONT> <FONT
STYLE="white-space:nowrap">40-F&#8194;&#9744;</FONT></P> <P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>INFORMATION CONTAINED IN THIS FORM <FONT STYLE="white-space:nowrap">6-K</FONT> REPORT
</B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Kazia Therapeutics Limited (the &#147;Company&#148;) is filing this Amendment No.&nbsp;1 on Form
<FONT STYLE="white-space:nowrap">6-K/A</FONT> (this &#147;<U>Amendment</U>&#148;) to amend its Report on Form <FONT STYLE="white-space:nowrap">6-K</FONT> furnished to the U.S. Securities and Exchange Commission on October&nbsp;15, 2024 (the
&#147;<U>Original Report</U>&#148;) announcing its plans to change the ratio of its American Depositary Shares (&#147;ADSs&#148;) to Ordinary Shares from one (1)&nbsp;ADS representing ten (10)&nbsp;Ordinary Shares to one (1)&nbsp;ADS representing
one hundred (100)&nbsp;Ordinary Shares (the &#147;ADS Ratio Change&#148;). This Amendment is being furnished solely for the purpose of clarifying the ADS Ratio Change by adding the following sentence to the beginning of the second paragraph of the
Original Report: &#147;The ADS Ratio Change will have the same effect as a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">one-for-ten</FONT></FONT> reverse ADS split for our ADS holders.&#148; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Other than as expressly set forth above, this Amendment does not, and does not purport to, amend, restate, or update the information contained
in the Original Report, or reflect any events that have occurred after the Original Report was filed. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SIGNATURE </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned,
thereunto duly authorized. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="100%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>Kazia Therapeutics Limited </B>(Registrant)</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ John Friend</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">John Friend</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Chief Executive Officer</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Date: 24&nbsp;October 2024</TD></TR>
</TABLE>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>2
<FILENAME>g887400g1023022454667.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g887400g1023022454667.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1"  ] -4# 2(  A$! Q$!_\0
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M'^&0=/S'%;35T9Q=F>Z#I43JA)+JIP,Y([5(.E<9\1_$7]A>&Y$B?%W=YBB
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..B@8M%)10 M%)10!__]D!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
